Appello Pharmaceuticals, Inc. (“Appello” or “Company”) today announced the completion of a $10.5 million Series A financing led by Deerfield Management and Mountain Group Partners (“MGP”). This initial investment will support the development of novel positive allosteric modulators (“PAMs”) of the metabotropic glutamate receptor subtype 4 (“mGlu4”) as an innovative new treatment for Parkinson’s disease.
Read the full press release: https://www.businesswire.com/news/home/20180628005166/en/Appello-Completes-10.5-Million-Series-Financing-Led
